This protocol is judged by an institutional evaluate board, an unbiased group that assessments any clinical trials involving human beings. If a research consists of a Schedule I drug, once the board approves the protocol as ethical, the researchers really have to make an application for an investigational new drug (IND) selection with the FDA.When